Another BriaCell Therapeutics Goal: A Better Treatment For Prostate Cancer

BriaCell Therapeutics Corp. (Nasdaq: BCTX|TSX: BCT), a clinical-stage biotechnology company specializing in targeted novel immuno-therapies to fight breast and prostate cancer, and in the early stages of researching similar therapies for non-small cell lung cancer and melanoma, is reporting success in such treatments.

The previous article on advanced breast cancer posted on TalkMarkets (see here) was extremely well received and this article focuses on prostate cancer and the research and development it is undertaking to advance the treatment of advanced prostate cancer.

About Prostate Cancer

Other than skin cancer, prostate cancer is the most common cancer in American men and the second leading cause of cancer death in American men, behind only lung cancer. The American Cancer Society’s estimates that there will be:

  • about 268,490 new cases of prostate cancer in the U.S. in 2022;
  • about 34,500 deaths from prostate cancer will occur during the year;
  • about 1 man in 8 will be diagnosed with prostate cancer during his lifetime of which about 1 man in 41 will die of prostate cancer but, while prostate cancer is a serious disease, most men diagnosed with prostate cancer do not die from it. In fact, more than 3.1 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today;
  • about 6 cases in 10 are diagnosed in men who are 65 or older (with an average age of 66 and more likely to develop in non-Hispanic black men), and it is rare in men under 40.

Immuno-therapies have become the forefront of cancer treatments in that they use the body’s immune system to destroy cancerous tumors to boost the body’s own cancer fighting cells which offers the potential for higher levels of safety and efficacy than chemotherapy, and even preventing cancer recurrence. Below is some of the research BriaCell is doing in that regard.


BriaCell has been developing Bria-Pros™, an off-the-shelf personalized immunotherapy for advanced prostate cancer, and has entered into a manufacturing service agreement with Waisman Biomanufacturing at the University of Wisconsin–Madison to manufacture Bria-Pros™ for anticipated use in clinical studies.

BriaCell’s Phase I/II trial in prostate cancer is expected to follow upon the completion of the manufacturing, testing, and the related regulatory filings.

(Click on image to enlarge)

4Q 2022 Financial Results

BriaCell Therapeutics is a clinical-stage startup with a market capitalization of only $108.5M. It is still in the product research and development of novel compounds and has no products and no revenue and requires a great deal of money to fund their R&D expenses. For a detailed look at all the financial metrics related to BriaCell in its last quarter (Q4 ending October 31st, 2022) and for every year going back to 2018 go here.

Summary highlights for Q4 showed:

  • a SG&A expense of $7.18M attributed to the resumption of clinical trials and increased laboratory activity, including the hiring of additional employees;
  • a net operating cash flow of $(4.1)M;
  • growth in net operating cash flow of 22.6%;
  • EBITDA of $(7.18)M;
  • EBITDA growth of -17.1%;
  • a net loss of $ (26.8)M or $(1.73) per share and
  • cash and equivalents on hand of $51.1M.

As disappointing as the above financial metrics are BriaCell's stock price declined "only" 49% in 2022 which is much less than the 6 major clinical-stage psychedelic stocks I track in the munKNEE Psychedelic Drug Stocks Index which, on average, went down 70% in 2022 (see details here).

Investment Risks

The only downsides I see in BriaCell's future are: 

  1. If it runs out of money to continue its research. The company reports, however, that their cash position of US$37 million is sufficient to advance the company through its key value-creating clinical milestones without the need to raise additional financing over the next 2 years,
  2. If another clinical-stage company develops a treatment for advanced prostate cancer before BriaCell. There is no evidence, however, that any other company is more advanced in their research for advanced prostate cancer than BriaCell.


Where else can one find an investment with the potential of treating such a huge number of gravely ill cancer patients? If, and when, it is bought out by a major pharmaceutical company, or brings a product directly to market itself, its stock price should go up dramatically.

Related Articles:
BriaCell Therapeutics' Mission: Destroy Breast Cancer
One-On-One With BriaCell Therapeutics Corp. Management
BriaCell Announces Positive End Of Phase II Meeting With The FDA For Bria-IMT(TM) Combination In Advanced Metastatic Breast Cancer

More By This Author:
2 ETFs Added To Best Cannabis Portfolio Performance Competition
The "Multi-Bagger" Portfolio Continued To Outperform The S&P 500 Last Week
How The 5 Cannabis Categories Performanced Last Week

Visit and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.